Crimson BioPharm

Crimson BioPharm is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for central nervous system (CNS) cancers. Founded by renowned Dana-Farber Cancer Institute and Harvard Medical School researchers Jean Zhao and Thomas Roberts, the company specializes in brain-penetrant small molecules. Its lead program, CM93, is a third-generation, covalent Epidermal Growth Factor Receptor (EGFR) inhibitor specifically engineered to cross the blood-brain barrier. The company is currently evaluating CM93 in Phase 1 clinical trials for patients with glioblastoma and is also exploring its application for lung cancer brain metastases. Crimson BioPharm is a participant in the NIH/NCI's Glioblastoma Therapeutics Network (GTN).